Through the biosurveillance efforts of the UP – Philippine Genome Center (PGC), in coordination with the Department of Health (DOH) – Epidemiology Bureau and the Inter-Agency Task Force (IATF) Task Force on COVID-19 Variants, we report the first confirmed case of the SARS-CoV-2 B.1.1.7 lineage, more commonly known as the UK variant, in the Philippines. An announcement of this finding can be found in an official DOH press release dated January 13, 2021.
Recently, new SARS-CoV-2 variants were detected in the United Kingdom and South Africa with multiple spike protein mutations that may cause substantial changes in certain properties of the virus. These observations spurred biosurveillance efforts in different countries, with some countries outside of the UK and South Africa already reporting the presence of these new variants within their territories. The data presented in this report is part of our own continuing biosurveillance efforts to track the entry of these new variants in the country, as well as other viral mutations that may be of concern locally.
In a report posted at the Global Initiative for Sharing All Influenza Data (GISAID) website, the UK variant is said to harbor multiple spike protein mutations within a single sample, including a combination of the following: H69del, V70del(69), Y145del(143), N501Y, A570D, D614G, P681H(674), T716I, S982A, and D1118H (GISAID, 2020). While the discovery of this new UK variant appears to be concerning, the report cautions that the detailed effects of these mutations remain to be fully determined.
COVID-19 or the Coronavirus Disease 2019 is caused by SARS-CoV-2 virus, the genome of which is a single-stranded positive sense RNA that is about 30,000 bases long. It contains 11 genes and several regions have been known to be immunogenic, including different parts of the Spike (S) protein, the Nucleocapsid (N) protein, as well as the Membrane (M) and Envelope (E) proteins, which have therefore been targeted for vaccine development.
Until vaccines and effective therapeutics become available, the practical way to transit safely out of the current lockdown may include the implementation of an effective testing, tracing and tracking system. However, this requires a reliable and clinically validated diagnostic platform for the sensitive and specific identification of SARS-CoV-2.